Aimei Health Technology Co., Ltd (AFJK) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
AFJK Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Aimei Health Technology Co., Ltd (AFJK) trades at a price-to-earnings ratio of 251.0x, with a stock price of $42.67 and trailing twelve-month earnings per share of $0.26.
The current P/E is 146% above its 5-year average of 102.2x. Over the past five years, AFJK's P/E has ranged from a low of 37.8x to a high of 376.5x, placing the current valuation at the 83th percentile of its historical range.
Compared to the Financial Services sector median P/E of 13.1x, AFJK trades at a 1810% premium to its sector peers. The sector includes 775 companies with P/E ratios ranging from 0.0x to 195.8x.
Relative to the broader market, AFJK commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AFJK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AFJK P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $250M | 5.7Lowest | - | +960%Best | |
| $589M | 9.2 | - | +225% | |
| $4B | 43.2 | 1.22 | -10% | |
| $973M | 33.3 | - | +104% | |
| $7B | 50.3 | - | -4% | |
| $5B | 23.5 | 0.30Best | +54% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AFJK Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $64.01 | $0.17 | 376.5x | +268% |
| FY2025 Q3 | $11.32 | $0.20 | 56.9x | -44% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $11.15 | $0.22 | 50.3x | -51% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $11.00 | $0.22 | 50.1x | -51% |
| FY2024 Q4 | $10.70 | $0.28 | 37.8x | -63% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $10.48 | $0.25 | 41.4x | -59% |
Average P/E for displayed period: 102.2x
See AFJK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AFJK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AFJK vs BRK-A
Side-by-side business, growth, and profitability comparison vs Berkshire Hathaway Inc..
Start ComparisonAFJK — Frequently Asked Questions
Quick answers to the most common questions about buying AFJK stock.
Is AFJK stock overvalued or undervalued?
AFJK trades at 251.0x P/E, above its 5-year average of 102.2x. The 83th percentile ranking indicates a premium to historical valuation.
How does AFJK's valuation compare to peers?
Aimei Health Technology Co., Ltd P/E of 251.0x compares to sector median of 13.1x. The premium reflects expected growth above peers.
What is AFJK's PEG ratio?
AFJK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.